Nautilus Biotechnology Aktie News

• Buck Institute's deployment of Nautilus' instrument generates tau proteoform data, providing external validation of the company's next-generation single-molecule proteomics platform  • Joint research results show high reproducibility across sites and insight into novel tau biology, signaling a fundamental shift in how proteomics technology can advance human health and longevity • Data present...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sujal Patel - Co-Founder, CEO, President, Secretary & Director Kentaro Suzuki - Chief Marketing Officer Anna Mowry - CFO & Treasurer Conference Call Participants Ji-Yon Yi William Ruby - TD Cowen, Research Division Presentation Operator Good day and thank you for standing by. Welc...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:50 PM EDT Company Participants Sujal Patel - Co-Founder, CEO, President, Secretary & Director Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hello. Hi. My name is Yuko Oku, and I work on the Life Science Tools and...

SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2025 Earnings Call July 31, 2025 8:30 AM ET Company Participants Anna Mowry - CFO & Treasurer Parag Mallick - Co-Founder, Chief Scientist & Director Sujal M. Patel - Co-Founder, CEO, President, Secretary & Director Conference Call Participants Daniel Gregory Brennan - TD Cowen, Research Division Subhalaxmi T.

SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2025.

SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2025 before market open on Thursday, July 31, 2025.